<DOC>
	<DOC>NCT00500305</DOC>
	<brief_summary>A patent ductus arteriosus (PDA) is associated with increased morbidity in premature infants. Standard indomethacin treatment is associated with intestinal and renal morbidity. B-type natriuretic peptide is elevated in significant PDAs. This study will determine whether BNP guided therapy could reduce doses of indomethacin.</brief_summary>
	<brief_title>The Use of B-Type Natriuretic Peptide (BNP) to Predict Closure of a Patent Ductus Arteriosus (PDA) in Premature Infants</brief_title>
	<detailed_description />
	<mesh_term>Ductus Arteriosus, Patent</mesh_term>
	<mesh_term>Natriuretic Peptide, Brain</mesh_term>
	<criteria>Infants with echocardiographically confirmed PDA Infants determined by attending physician to require PDA closure infants with congenital hearts disease infants with creatinine value &gt; 2.0</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>4 Months</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>indomethacin therapy</keyword>
	<keyword>patent ductus arteriosus</keyword>
</DOC>